Acute leukemia evolving from multiple myeloma and co-expressing myeloid and plasma cell antigens.
This report describes the development of acute myeloblastic leukemia in a patient after long-term alkylator therapy for multiple myeloma. Despite chromosome deletions -5, -7, the patient lacked the histochemistry and clinical findings characteristic of therapy-induced leukemia. In double-labeled surface marker studies by flow cytometry, the leukemic blast cells co-expressed myeloid and plasma cell surface markers. The findings may support the hypothesis of a single stem cell abnormality's being responsible for both the malignant plasma cells and the myeloid leukemic cells.
Stewart
A K
AK
Department of Medicine, St. Michael's Hospital, University of Toronto, Canada.
Freedman
J
J
Garvey
M B
MB
D000208:Acute Disease; D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis; D001853:Bone Marrow / Q000276:immunology*; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology* / Q000276:immunology; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000235:genetics / Q000473:pathology; D010950:Plasma Cells / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D013997:Time Factors
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D008558:Melphalan; D011241:Prednisone